Reteplase
Retavase, Rapilysin (reteplase) is an enzyme pharmaceutical. Reteplase was first approved as Retavase on 1996-08-29. It is used to treat myocardial infarction and ventricular dysfunction in the USA. It has been approved in Europe to treat myocardial infarction.
| Trade Name | Rapilysin |
|---|---|
| Common Name | Reteplase |
| Indication | myocardial infarction, ventricular dysfunction |
| Drug Class | Enzymes: tissue-type plasminogen activators |
